Evidence map›Paper›PMID 38671183›Full record

ReviewInternational journal of hematology2024

CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.

Feng-Ming Tien, Hsin-An Hou

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Feng-Ming TienDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Hsin-An HouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. hsinanhou@ntu.edu.tw.
National Taiwan University · TWNational Taiwan University Hospital · TW

Funding

Ministry of Health and Welfare 107-TDU-B-211-114009Ministry of Health and Welfare 111-TDU-B-221-114001Ministry of Science and Technology, Taiwan 108-2628-B-002-015Ministry of Science and Technology, Taiwan 109-2314-B-002-213Ministry of Science and Technology, Taiwan 111-2314-B-002-279Ministry of Science and Technology, Taiwan 112-2314-B-002-197
6 · The paper itself

Abstract

Mutations in CCAAT enhancer binding protein α (CEBPA) occur in approximately 10% of patients with de novo acute myeloid leukemia (AML). Emerging evidence supports that in-frame mutations in the basic leucine zipper domain of CEBPA (CEBPA

Indexed as

Leukemia, Myeloid, AcuteMutationCCAAT-Enhancer-Binding Protein-alphaCCAAT-Enhancer-Binding ProteinsHumansPrognosisRisk AssessmentCCAAT-Enhancer-Binding Protein-alphaCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanAcute myeloid leukemiaCEBPALeukemogenesisPrognosis

Identifiers

PMID38671183
OpenAlexW4395676922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.